The company said it signed a lease agreement for a new facility in Englewood, with physical relocation planned for the end of the 1st quarter of 2017, pending the build-out of the office and warehouse facilities.
“Last year was a dynamic period of growth for Viveve including FDA clearance for our Viveve System in the U.S. Establishment of our new corporate headquarters in Colorado positions us to continue to build momentum as we work to maximize the commercial opportunities for the Viveve System around the world and as we plan to introduce new innovations in women’s health in the years ahead. The greater-Denver area is a dynamic business center — especially for medical technology companies. We’re enthusiastic that Colorado will provide a very attractive quality of life for our employees in addition to having a strong economy, positive growth outlook and highly educated workforce,” CEO Patricia Scheller said in a press release.
Viveve said it will take up residence in a new 12,400 square foot facility which will serve as corporate offices and warehouse operations.
“We are pleased that Viveve has chosen Colorado for the relocation of its headquarters. Colorado’s pro-business and collaborative environment, as well as our robust workforce and global reach, continues to attract and retain exceptional companies,” Colorado Governor John Hickenlooper said in prepared remarks.
“Colorado offers a lower cost of doing business than our peer markets, and coastal cities and companies like Viveve are seizing this competitive advantage. We know that Viveve will find great success here,” OEDIT global business development director Michelle Hadwiger said in a prepared statement.
Last October, Viveve said it won FDA 510(k) clearance for its Viveve System, now cleared for use in general surgical procedures for electrocoagulation and hemostasis.
The company’s Viveve System is designed as a non-surgical treatment for post-partum laxity of the vaginal introitus.
In early September, Viveve said it won regulatory clearance from Australia’s Therapeutic Goods Administration, and a month earlier claimed a win from the Ministry of Food and Drug Safety in South Korea for the Viveve system.